Table 2. The relationship between clinicopathological parameters and serum MAPT-AS1 in BC patients.
| Clinicopathological parameters | n | MAPT-AS1 | χ2 | P | |
|---|---|---|---|---|---|
| Low expression | High expression | ||||
| Age, n (%) | 0.851 | 0.356 | |||
| ≤52 years | 300 | 150 (50.0) | 150 (50.0) | ||
| >52 years | 198 | 108 (54.5) | 90 (45.5) | ||
| Size, n (%) | 13.046 | <0.0001**** | |||
| ≤3 cm | 318 | 179 (56.3) | 139 (43.7) | ||
| >3 cm | 180 | 71 (39.4) | 109 (60.6) | ||
| Grade, n (%) | 5.169 | 0.023* | |||
| I and II | 302 | 164 (54.3) | 138 (45.7) | ||
| III | 196 | 86 (43.9) | 110 (56.1) | ||
| Stage, n (%) | |||||
| I/II | 252 | 172 (69.1) | 77 (30.9) | 70.973 | <0.0001**** |
| III/IV | 246 | 78 (31.3) | 171 (68.7) | ||
| Lymphatic metastasis, n (%) | 2.924 | 0.087 | |||
| Yes | 210 | 96 (45.7) | 114 (54.3) | ||
| No | 288 | 154 (53.5) | 134 (46.5) | ||
| Estrogen receptor, n (%) | 0.064 | 0.8 | |||
| Negative | 158 | 78 (49.4) | 80 (50.6) | ||
| Positive | 340 | 172 (50.6) | 168 (49.4) | ||
| Progesterone receptor, n (%) | 0.004 | 0.948 | |||
| Negative | 174 | 87 (50.0) | 87 (50.0) | ||
| Positive | 324 | 163 (50.3) | 161 (49.7) | ||
| HER2, n (%) | 6.368 | 0.012* | |||
| Negative | 145 | 60 (41.4) | 85 (58.6) | ||
| Positive | 353 | 190 (53.8) | 163 (46.2) | ||
| Ki-67, n (%) | 0.727 | 0.394 | |||
| ≤14 | 135 | 72 (53.3) | 63 (46.7) | ||
| >14 | 363 | 178 (49.0) | 185 (51.0) | ||
*, P <0.05; ****, P<0.0001. BC, breast cancer; HER2, human epidermal growth factor receptor 2.